GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » ROC (Joel Greenblatt) %
中文

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) ROC (Joel Greenblatt) % : -12,697.44% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Fresh Tracks Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -12,697.44%.

The historical rank and industry rank for Fresh Tracks Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

FRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35660.63   Med: -6383.36   Max: -155.87
Current: -7814.56

During the past 13 years, Fresh Tracks Therapeutics's highest ROC (Joel Greenblatt) % was -155.87%. The lowest was -35660.63%. And the median was -6383.36%.

FRTX's ROC (Joel Greenblatt) % is ranked worse than
90.4% of 1469 companies
in the Biotechnology industry
Industry Median: -339.22 vs FRTX: -7814.56

Fresh Tracks Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -7.30% per year.


Fresh Tracks Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Fresh Tracks Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics ROC (Joel Greenblatt) % Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15,840.73 -14,991.40 -35,660.63 -17,504.56 -7,201.27

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16,229.60 -15,973.83 -11,269.14 14,510.34 -12,697.44

Competitive Comparison of Fresh Tracks Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Fresh Tracks Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's ROC (Joel Greenblatt) % falls into.



Fresh Tracks Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.993) - (1.735 + 0 + 0.373)
=-1.115

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.045 + 0 + 0.639) - (0.406 + 0 + 1.25)
=-0.972

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Fresh Tracks Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-4.952/( ( (0.044 + max(-1.115, 0)) + (0.034 + max(-0.972, 0)) )/ 2 )
=-4.952/( ( 0.044 + 0.034 )/ 2 )
=-4.952/0.039
=-12,697.44 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh Tracks Therapeutics  (OTCPK:FRTX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Fresh Tracks Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Headlines

From GuruFocus

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

By Stock market mentor Stock market mentor 01-27-2023